{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T19:40:22Z","timestamp":1731958822332,"version":"3.28.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,18]]},"DOI":"10.7759\/cureus.73929","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T19:03:37Z","timestamp":1731956617000},"source":"Crossref","is-referenced-by-count":0,"title":["Biometrics and Biomarkers in Patients With Psoriasis"],"prefix":"10.7759","author":[{"given":"Sebastian","family":"Arango","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kawaiola Cael","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shakil  O","family":"Huq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Blanca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc M","family":"Kesselman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim WB","year":"2017","unstructured":"Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017, 63:278-85.","journal-title":"Can Fam Physician"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 study","volume":"8","author":"Damiani G","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, et al.. The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 study. Front Med (Lausanne). 2021, 8:743180. 10.3389\/fmed.2021.743180","journal-title":"Front Med (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States","volume":"157","author":"Armstrong AW","year":"2021","unstructured":"Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CE. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021, 157:940-6. 10.1001\/jamadermatol.2021.2007","journal-title":"JAMA Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.12.032","article-title":"Racial differences in perceptions of psoriasis therapies: implications for racial disparities in psoriasis treatment","volume":"139","author":"Takeshita J","year":"2019","unstructured":"Takeshita J, Eriksen WT, Raziano VT, et al.. Racial differences in perceptions of psoriasis therapies: implications for racial disparities in psoriasis treatment. J Invest Dermatol. 2019, 139:1672-1679.e1. 10.1016\/j.jid.2018.12.032","journal-title":"J Invest Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.02.013","article-title":"Health-related QOL differs by race\/ethnicity in North American patients with psoriasis: results from PSOLAR","volume":"142","author":"Takeshita J","year":"2022","unstructured":"Takeshita J, Augustin M, de Jong EM, et al.. Health-related QOL differs by race\/ethnicity in North American patients with psoriasis: results from PSOLAR. J Invest Dermatol. 2022, 142:2528-2531.e3. 10.1016\/j.jid.2022.02.013","journal-title":"J Invest Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou X","year":"2022","unstructured":"Zhou X, Chen Y, Cui L, Shi Y, Guo C. Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis. 2022, 13:81. 10.1038\/s41419-022-04523-3","journal-title":"Cell Death Dis"},{"key":"ref7","article-title":"Current developments in the immunology of psoriasis","volume":"93","author":"Gr\u00e4n F","year":"2020","unstructured":"Gr\u00e4n F, Kerstan A, Serfling E, Goebeler M, Muhammad K. Current developments in the immunology of psoriasis. Yale J Biol Med. 2020, 93:97-110.","journal-title":"Yale J Biol Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S420850","article-title":"Cellular mechanisms of psoriasis pathogenesis: a systemic review","volume":"16","author":"Wu M","year":"2023","unstructured":"Wu M, Dai C, Zeng F. Cellular mechanisms of psoriasis pathogenesis: a systemic review. Clin Cosmet Investig Dermatol. 2023, 16:2503-15. 10.2147\/CCID.S420850","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.15386\/cjmed-494","article-title":"VEGF involvement in psoriasis","volume":"88","author":"Marina ME","year":"2015","unstructured":"Marina ME, Roman II, Constantin AM, Mihu CM, T\u0103taru AD. VEGF involvement in psoriasis. Clujul Med. 2015, 88:247-52. 10.15386\/cjmed-494","journal-title":"Clujul Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon A","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019, 20:1475. 10.3390\/ijms20061475","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.47162\/RJME.62.4.02","article-title":"Novel concepts in psoriasis: histopathology and markers related to modern treatment approaches","volume":"62","author":"Mihu C","year":"2021","unstructured":"Mihu C, Neag MA, Boc\u015fan IC, et al.. Novel concepts in psoriasis: histopathology and markers related to modern treatment approaches. Rom J Morphol Embryol. 2021, 62:897-906. 10.47162\/RJME.62.4.02","journal-title":"Rom J Morphol Embryol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes JE","year":"2017","unstructured":"Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017, 140:645-53. 10.1016\/j.jaci.2017.07.004","journal-title":"J Allergy Clin Immunol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17141","article-title":"Increased risk of death in patients with psoriasis: disease or lifestyle?","volume":"180","author":"Danielsen K","year":"2019","unstructured":"Danielsen K. Increased risk of death in patients with psoriasis: disease or lifestyle?. Br J Dermatol. 2019, 180:3-4. 10.1111\/bjd.17141","journal-title":"Br J Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16919","article-title":"Cause-specific mortality in patients with psoriasis and psoriatic arthritis","volume":"180","author":"Skov L","year":"2019","unstructured":"Skov L, Thomsen SF, Kristensen LE, Dodge R, Hedegaard MS, Kjellberg J. Cause-specific mortality in patients with psoriasis and psoriatic arthritis. Br J Dermatol. 2019, 180:100-7. 10.1111\/bjd.16919","journal-title":"Br J Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050500","article-title":"Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production","volume":"202","author":"Nestle FO","year":"2005","unstructured":"Nestle FO, Conrad C, Tun-Kyi A, et al.. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med. 2005, 202:135-43. 10.1084\/jem.20050500","journal-title":"J Exp Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S252578","article-title":"Biologic treatments of psoriasis: an update for the clinician","volume":"15","author":"Brownstone ND","year":"2021","unstructured":"Brownstone ND, Hong J, Mosca M, Hadeler E, Liao W, Bhutani T, Koo J. Biologic treatments of psoriasis: an update for the clinician. Biologics. 2021, 15:39-51. 10.2147\/BTT.S252578","journal-title":"Biologics"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities","volume":"11","author":"Menter A","year":"2021","unstructured":"Menter A, Krueger GG, Paek SY, Kivelevitch D, Adamopoulos IE, Langley RG. Interleukin-17 and interleukin-23: a narrative review of mechanisms of action in psoriasis and associated comorbidities. Dermatol Ther (Heidelb). 2021, 11:385-400. 10.1007\/s13555-021-00483-2","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1302313","article-title":"Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis","volume":"192","author":"Cheuk S","year":"2014","unstructured":"Cheuk S, Wik\u00e9n M, Blomqvist L, Nyl\u00e9n S, Talme T, St\u00e5hle M, Eidsmo L. Epidermal Th22 and Tc17 cells form a localized disease memory in clinically healed psoriasis. J Immunol. 2014, 192:3111-20. 10.4049\/jimmunol.1302313","journal-title":"J Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints","volume":"19","author":"Boutet MA","year":"2018","unstructured":"Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018, 19:530. 10.3390\/ijms19020530","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.3682","article-title":"Association between inflammatory bowel disease and both psoriasis and psoriatic arthritis: a bidirectional 2-sample Mendelian randomization study","volume":"158","author":"Freuer D","year":"2022","unstructured":"Freuer D, Linseisen J, Meisinger C. Association between inflammatory bowel disease and both psoriasis and psoriatic arthritis: a bidirectional 2-sample Mendelian randomization study. JAMA Dermatol. 2022, 158:1262-8. 10.1001\/jamadermatol.2022.3682","journal-title":"JAMA Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02713.x","article-title":"Serologic markers of celiac disease in psoriatic patients","volume":"22","author":"Damasiewicz-Bodzek A","year":"2008","unstructured":"Damasiewicz-Bodzek A, Wielkoszy\u0144ski T. Serologic markers of celiac disease in psoriatic patients. J Eur Acad Dermatol Venereol. 2008, 22:1055-61. 10.1111\/j.1468-3083.2008.02713.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2009.09.351","article-title":"Serum cytokine elevations in celiac disease: association with disease presentation","volume":"71","author":"Manavalan JS","year":"2010","unstructured":"Manavalan JS, Hernandez L, Shah JG, et al.. Serum cytokine elevations in celiac disease: association with disease presentation. Hum Immunol. 2010, 71:50-7. 10.1016\/j.humimm.2009.09.351","journal-title":"Hum Immunol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5114\/ada.2018.78028","article-title":"Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis","volume":"37","author":"Pietrzak A","year":"2020","unstructured":"Pietrzak A, Chabros P, Grywalska E, et al.. Serum concentration of interleukin 6 is related to inflammation and dyslipidemia in patients with psoriasis. Postepy Dermatol Alergol. 2020, 37:41-5. 10.5114\/ada.2018.78028","journal-title":"Postepy Dermatol Alergol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.20398","article-title":"Celiac disease-associated antibodies in patients with psoriasis and correlation with HLA Cw6","volume":"24","author":"Singh S","year":"2010","unstructured":"Singh S, Sonkar GK, Usha, Singh S. Celiac disease-associated antibodies in patients with psoriasis and correlation with HLA Cw6. J Clin Lab Anal. 2010, 24:269-72. 10.1002\/jcla.20398","journal-title":"J Clin Lab Anal"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06137.x","article-title":"Coeliac disease-associated antibodies correlate with psoriasis activity","volume":"151","author":"Woo WK","year":"2004","unstructured":"Woo WK, McMillan SA, Watson RG, McCluggage WG, Sloan JM, McMillan JC. Coeliac disease-associated antibodies correlate with psoriasis activity. Br J Dermatol. 2004, 151:891-4. 10.1111\/j.1365-2133.2004.06137.x","journal-title":"Br J Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2010.03980.x","article-title":"Estimation of (IgA) anti-gliadin, anti-endomysium and tissue transglutaminase in the serum of patients with psoriasis","volume":"36","author":"Nagui N","year":"2011","unstructured":"Nagui N, El Nabarawy E, Mahgoub D, Mashaly HM, Saad NE, El-Deeb DF. Estimation of (IgA) anti-gliadin, anti-endomysium and tissue transglutaminase in the serum of patients with psoriasis. Clin Exp Dermatol. 2011, 36:302-4. 10.1111\/j.1365-2230.2010.03980.x","journal-title":"Clin Exp Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2013.25.3.298","article-title":"Coeliac disease-associated antibodies in psoriasis","volume":"25","author":"Akbulut S","year":"2013","unstructured":"Akbulut S, G\u00fcr G, Topal F, Senel E, Topal FE, Alli N, Saritas U. Coeliac disease-associated antibodies in psoriasis. Ann Dermatol. 2013, 25:298-303. 10.5021\/ad.2013.25.3.298","journal-title":"Ann Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.55730\/1300-0144.5615","article-title":"Screening of antigliadin and antitissue transglutaminase antibodies in patients with chronic plaque psoriasis: a case-control study","volume":"53","author":"Engin B","year":"2023","unstructured":"Engin B, Huseynova C, Ak T, Ayla AY, Can G, U\u011furlu S. Screening of antigliadin and antitissue transglutaminase antibodies in patients with chronic plaque psoriasis: a case-control study. Turk J Med Sci. 2023, 53:544-51. 10.55730\/1300-0144.5615","journal-title":"Turk J Med Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes JE","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018, 201:1605-13. 10.4049\/jimmunol.1800013","journal-title":"J Immunol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2016.1174328","article-title":"Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis","volume":"27","author":"Muramatsu S","year":"2017","unstructured":"Muramatsu S, Kubo R, Nishida E, Morita A. Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis. Mod Rheumatol. 2017, 27:137-41. 10.3109\/14397595.2016.1174328","journal-title":"Mod Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1155\/MI.2005.273","article-title":"Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity","volume":"2005","author":"Arican O","year":"2005","unstructured":"Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005, 2005:273-9. 10.1155\/MI.2005.273","journal-title":"Mediators Inflamm"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s10495-020-01623-3","article-title":"Elevated IL-22 in psoriasis plays an anti-apoptotic role in keratinocytes through mediating Bcl-xL\/Bax","volume":"25","author":"Wang B","year":"2020","unstructured":"Wang B, Han D, Li F, et al.. Elevated IL-22 in psoriasis plays an anti-apoptotic role in keratinocytes through mediating Bcl-xL\/Bax. Apoptosis. 2020, 25:663-73. 10.1007\/s10495-020-01623-3","journal-title":"Apoptosis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293327","article-title":"Circulating inflammatory cytokines and psoriasis risk: a systematic review and meta-analysis","volume":"18","author":"Liu XQ","year":"2023","unstructured":"Liu XQ, Zhou PL, Yin XY, Wang AX, Wang DH, Yang Y, Liu Q. Circulating inflammatory cytokines and psoriasis risk: a systematic review and meta-analysis. PLoS One. 2023, 18:e0293327. 10.1371\/journal.pone.0293327","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.5455\/msm.2022.33.40-43","article-title":"Serum levels of tumor necrosis factor - alpha in patients with psoriasis","volume":"34","author":"Ovcina-Kurtovic N","year":"2022","unstructured":"Ovcina-Kurtovic N, Kasumagic-Halilovic E. Serum levels of tumor necrosis factor - alpha in patients with psoriasis. Mater Sociomed. 2022, 34:40-3. 10.5455\/msm.2022.33.40-43","journal-title":"Mater Sociomed"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3709749","article-title":"Role of neutrophils in psoriasis","volume":"2020","author":"Wang WM","year":"2020","unstructured":"Wang WM, Jin HZ. Role of neutrophils in psoriasis. J Immunol Res. 2020, 2020:3709749. 10.1155\/2020\/3709749","journal-title":"J Immunol Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1043380","article-title":"Exploring the association and causal effect between white blood cells and psoriasis using large-scale population data","volume":"14","author":"Zhou G","year":"2023","unstructured":"Zhou G, Ren X, Tang Z, et al.. Exploring the association and causal effect between white blood cells and psoriasis using large-scale population data. Front Immunol. 2023, 14:1043380. 10.3389\/fimmu.2023.1043380","journal-title":"Front Immunol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S121302","article-title":"Systemic abnormalities of psoriatic patients: a retrospective study","volume":"9","author":"Yin L","year":"2016","unstructured":"Yin L, Xu JL, Hu YY, Johnston A, Yin ZQ. Systemic abnormalities of psoriatic patients: a retrospective study. Clin Cosmet Investig Dermatol. 2016, 9:443-9. 10.2147\/CCID.S121302","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.02.041","article-title":"Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients","volume":"148","author":"Rodriguez-Rosales YA","year":"2021","unstructured":"Rodriguez-Rosales YA, Langereis JD, Gorris MA, et al.. Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients. J Allergy Clin Immunol. 2021, 148:1030-40. 10.1016\/j.jaci.2021.02.041","journal-title":"J Allergy Clin Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-077596","article-title":"Association between the neutrophil-to-lymphocyte ratio and psoriasis: a cross-sectional study of the National Health and Nutrition Examination Survey 2011-2014","volume":"13","author":"Hong J","year":"2023","unstructured":"Hong J, Lian N, Li M. Association between the neutrophil-to-lymphocyte ratio and psoriasis: a cross-sectional study of the National Health and Nutrition Examination Survey 2011-2014. BMJ Open. 2023, 13:e077596. 10.1136\/bmjopen-2023-077596","journal-title":"BMJ Open"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-021-00454-4","article-title":"Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and other hematological parameters in psoriasis patients","volume":"22","author":"Wang WM","year":"2021","unstructured":"Wang WM, Wu C, Gao YM, Li F, Yu XL, Jin HZ. Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and other hematological parameters in psoriasis patients. BMC Immunol. 2021, 22:64. 10.1186\/s12865-021-00454-4","journal-title":"BMC Immunol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02376","article-title":"Neutrophils in psoriasis","volume":"10","author":"Chiang CC","year":"2019","unstructured":"Chiang CC, Cheng WJ, Korinek M, Lin CY, Hwang TL. Neutrophils in psoriasis. Front Immunol. 2019, 10:2376. 10.3389\/fimmu.2019.02376","journal-title":"Front Immunol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2011.02570.x","article-title":"Basophil recruitment and activation in inflammatory skin diseases","volume":"66","author":"Ito Y","year":"2011","unstructured":"Ito Y, Satoh T, Takayama K, Miyagishi C, Walls AF, Yokozeki H. Basophil recruitment and activation in inflammatory skin diseases. Allergy. 2011, 66:1107-13. 10.1111\/j.1398-9995.2011.02570.x","journal-title":"Allergy"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2017.07.003","article-title":"Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis","volume":"88","author":"Mashiko S","year":"2017","unstructured":"Mashiko S, Mehta H, Bissonnette R, Sarfati M. Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis. J Dermatol Sci. 2017, 88:167-74. 10.1016\/j.jdermsci.2017.07.003","journal-title":"J Dermatol Sci"},{"key":"ref44","article-title":"Atopy","author":"Justiz Vaillant AA","year":"2024","unstructured":"Justiz Vaillant AA, Modi P, Jan A. Atopy. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref45","article-title":"Creatine phosphokinase","author":"Aujla RS","year":"2024","unstructured":"Aujla RS, Zubair M, Patel R. Creatine phosphokinase. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-199412000-00011","article-title":"Identification and activity of cytosol creatine phosphokinase enzymes in normal and diseased skin","volume":"308","author":"Zemtsov A","year":"1994","unstructured":"Zemtsov A, Cameron GS, Bradley CA, Montalvo-Lugo V, Mattioli F. Identification and activity of cytosol creatine phosphokinase enzymes in normal and diseased skin. Am J Med Sci. 1994, 308:365-9. 10.1097\/00000441-199412000-00011","journal-title":"Am J Med Sci"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.01697.x","article-title":"Creatine kinase and creatine transporter in normal, wounded, and diseased skin","volume":"118","author":"Schlattner U","year":"2002","unstructured":"Schlattner U, M\u00f6ckli N, Speer O, Werner S, Wallimann T. Creatine kinase and creatine transporter in normal, wounded, and diseased skin. J Invest Dermatol. 2002, 118:416-23. 10.1046\/j.0022-202x.2001.01697.x","journal-title":"J Invest Dermatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-011-0166-x","article-title":"Pathogenesis of dermatomyositis: role of cytokines and interferon","volume":"13","author":"Kao L","year":"2011","unstructured":"Kao L, Chung L, Fiorentino DF. Pathogenesis of dermatomyositis: role of cytokines and interferon. Curr Rheumatol Rep. 2011, 13:225-32. 10.1007\/s11926-011-0166-x","journal-title":"Curr Rheumatol Rep"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2017.09.005","article-title":"Psoriasis and the metabolic syndrome","volume":"36","author":"Gisondi P","year":"2018","unstructured":"Gisondi P, Fostini AC, Foss\u00e0 I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018, 36:21-8. 10.1016\/j.clindermatol.2017.09.005","journal-title":"Clin Dermatol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2017.09.004","article-title":"Pathophysiology of the metabolic syndrome","volume":"36","author":"McCracken E","year":"2018","unstructured":"McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018, 36:14-20. 10.1016\/j.clindermatol.2017.09.004","journal-title":"Clin Dermatol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1159\/000455840","article-title":"Psoriasis and obesity","volume":"232","author":"Jensen P","year":"2016","unstructured":"Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016, 232:633-9. 10.1159\/000455840","journal-title":"Dermatology"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-022-01062-4","article-title":"Cell death and inflammation during obesity: \"know my methods, WAT(son)\"","volume":"30","author":"Hildebrandt X","year":"2023","unstructured":"Hildebrandt X, Ibrahim M, Peltzer N. Cell death and inflammation during obesity: \"know my methods, WAT(son)\". Cell Death Differ. 2023, 30:279-92. 10.1038\/s41418-022-01062-4","journal-title":"Cell Death Differ"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339","article-title":"Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi R","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013, 133:377-85. 10.1038\/jid.2012.339","journal-title":"J Invest Dermatol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(07)61129-5","article-title":"Current and future management of psoriasis","volume":"370","author":"Menter A","year":"2007","unstructured":"Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007, 370:272-84. 10.1016\/s0140-6736(07)61129-5","journal-title":"Lancet"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1192543","article-title":"Advances in psoriasis and gut microorganisms with co-metabolites","volume":"14","author":"Zhu Q","year":"2023","unstructured":"Zhu Q, Wu K, Yang Q, Meng B, Niu Y, Zhao F. Advances in psoriasis and gut microorganisms with co-metabolites. Front Microbiol. 2023, 14:1192543. 10.3389\/fmicb.2023.1192543","journal-title":"Front Microbiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/298681-biometrics-and-biomarkers-in-patients-with-psoriasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T19:03:39Z","timestamp":1731956619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/298681-biometrics-and-biomarkers-in-patients-with-psoriasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":55,"URL":"https:\/\/doi.org\/10.7759\/cureus.73929","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,18]]}}}